ado-trastuzumab emtansine 160 MG Injection [KADCYLA]

Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.

Start free with Eleplan

Clinical drug

ado-trastuzumab emtansine 160 MG Injection [KADCYLA]

160 MG · Injection · injection

A form of ado-trastuzumab emtansine →

ado-trastuzumab emtansine 160 MG Injection [KADCYLA] — HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors. Strength, form, class, interactions & more.

ado-trastuzumab emtansine 160 MG Injection [KADCYLA]

Classification

HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsHER2/neu Receptor Antagonist

Drug interactions

Concomitant use of strong CYP3A4 inhibitors with ado-trastuzumab emtansine should be avoided due to potential increased toxicity.

  • majorstrong CYP3A4 inhibitors — increased DM1 exposure and toxicity

Real-world adverse events (FAERS)

Disease Progression781Fatigue751Nausea732Off Label Use637Diarrhoea594Death541Thrombocytopenia468Neuropathy Peripheral453

Source: RxNorm + openFDA + RxClass + FAERS · 2026

Look up another medication

Powered by Eleplan

A drug lookup is just the start. Eleplan keeps the whole care plan in one place.

Medications, diagnoses, documents, appointments, and the whole care team — organized and always in sync, with Ellie, your AI care assistant, on top of it. Free to start.